Patent · US Active

Formulations of histone deacetylase inhibitor and uses therof

US9403032B2 · kind B2 · utility

2Cited by
35References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 31, 2013
Grant dateAug 2, 2016
Priority date—
Expiry dateOct 31, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D307/85
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.